1887

Journal of Medical Microbiology logo

Volume 65, Issue 8

5-Fluorouracil sensitivity varies among oral micro-organisms Free

Abstract

5-Fluorouracil (5-FU), a commonly used chemotherapeutic agent, often causes oral mucositis, an inflammation and ulceration of the oral mucosa. Micro-organisms in the oral cavity are thought to play an important role in the aggravation and severity of mucositis, but the mechanisms behind this remain unclear. Although 5-FU has been shown to elicit antibacterial effects at high concentrations (>100 µM), its antibacterial effect at physiologically relevant concentrations in the oral cavity is unknown. This study reports the effect of different concentrations of 5-FU (range 0.1–50 µM) on the growth and viability of bacterial monocultures that are present in the oral cavity and the possible role in the activity of dihydropyrimidine dehydrogenase (DPD), an enzyme involved in 5-FU resistance. Our data showed a differential sensitivity among the tested oral species towards physiological concentrations of 5-FU. , ,,, and appeared to be highly resistant to all tested concentrations. In contrast, , ,, and showed a significant reduction in growth and viability starting from very low concentrations (0.2–3.1 µM). We can also provide evidence that DPD is not involved in the 5-FU resistance of the selected species. The observed variability in response to physiological 5-FU concentrations may explain why certain microbiota lead to a community dysbiosis and/or an overgrowth of certain resistant micro-organisms in the oral cavity following cancer treatment.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): bacteria , Chemotherapy , clinical microbiology , flow cytometry , growth kinetics and mouth
© 2016 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000292
2016-08-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/65/8/775.html?itemId=/content/journal/jmm/10.1099/jmm.0.000292&mimeType=html&fmt=ahah

References

  1. Aziz Q., Doré J., Emmanuel A., Guarner F., Quigley E. M. 2013; Gut microbiota and gastrointestinal health: current concepts and future directions. Neurogastroenterol Motil 25:4–15 [View Article][PubMed]
     [Google Scholar]
  2. Beck A., Etienne M. C., Chéradame S., Fischel J. L., Formento P., Renée N., Milano G. 1994; A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 30:1517–1522 [View Article]
     [Google Scholar]
  3. Berney M., Hammes F., Bosshard F., Weilenmann H. U., Egli T. 2007; Assessment and interpretation of bacterial viability by using the LIVE/DEAD BacLight Kit in combination with flow cytometry. Appl Environ Microbiol 73:3283–3290 [View Article][PubMed]
     [Google Scholar]
  4. Bocci G., Danesi R., Di Paolo A. D., Innocenti F., Allegrini G., Falcone A., Melosi A., Battistoni M., Barsanti G. et al. 2000; Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res 6:3032–3037[PubMed]
     [Google Scholar]
  5. Bodet C. A., Jorgensen J. H., Drutz D. J. 1985; Antibacterial activities of antineoplastic agents. Antimicrob Agents Chemother 28:437–439 [View Article][PubMed]
     [Google Scholar]
  6. Carnel S. B., Blakeslee D. B., Oswald S. G., Barnes M. 1990; Treatment of radiation- and chemotherapy-induced stomatitis. Otolaryngol Head Neck Surg 102:326–330 [View Article][PubMed]
     [Google Scholar]
  7. Casale F., Canaparo R., Serpe L., Muntoni E., Pepa C. D., Costa M., Mairone L., Zara G. P., Fornari G., Eandi M. 2004; Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. Pharmacol Res 50:173–179 [View Article][PubMed]
     [Google Scholar]
  8. Clark J. L., Berger S. H., Mittelman A., Berger F. G. 1987; Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy. Cancer Treat Rep 71:261–265[PubMed]
     [Google Scholar]
  9. Dewhirst F. E., Chen T., Izard J., Paster B. J., Tanner A. C., Yu W. H., Lakshmanan A., Wade W. G. 2010; The human oral microbiome. J Bacteriol 192:5002–5017 [View Article][PubMed]
     [Google Scholar]
  10. Diasio R. B., Beavers T. L., Carpenter J. T. 1988; Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81:47–51 [View Article][PubMed]
     [Google Scholar]
  11. Diasio R. B., Harris B. E. 1989; Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215–237 [View Article][PubMed]
     [Google Scholar]
  12. Goldschmidt M. C., Bodey G. P. 1972; Effect of chemotherapeutic agents upon microorganisms isolated from cancer patients. Antimicrob Agents Chemothera 1:348–353 [View Article]
     [Google Scholar]
  13. Grem J. L. 2000; 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 18:299–313[PubMed] [CrossRef]
     [Google Scholar]
  14. Harris B. E., Carpenter J. T., Diasio R. B. 1991; Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer 68:499–501 [View Article][PubMed]
     [Google Scholar]
  15. Hidese R., Mihara H., Kurihara T., Esaki N. 2011; Escherichia coli dihydropyrimidine dehydrogenase is a novel NAD-dependent heterotetramer essential for the production of 5,6-dihydrouracil. J Bacteriol 193:989–993 [View Article][PubMed]
     [Google Scholar]
  16. Johnston P. G., Lenz H. J., Leichman C. G., Danenberg K. D., Allegra C. J., Danenberg P. V., Leichman L. 1995; Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407–1412[PubMed]
     [Google Scholar]
  17. Joulia J. M., Pinguet F., Ychou M., Duffour J., Astre C., Bressolle F. 1999; Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid. Eur J Cancer 35:296–301 [View Article][PubMed]
     [Google Scholar]
  18. Kahm M., Hasenbrink G., Lichtenberg-Fraté H., Ludwig J., Kschischo M. 2010; Grofit: fitting biological growth curves with R. J Stat Softw 33:1–21 [View Article]
     [Google Scholar]
  19. Kim S., West T. P. 1991; Pyrimidine catabolism in Pseudomonas aeruginosa . FEMS Microbiol Lett 77:175–179 [View Article]
     [Google Scholar]
  20. Kim S., Park D. H., Shim J. 2008; Thymidylate synthase and dihydropyrimidine dehydrogenase levels are associated with response to 5-fluorouracil in Caenorhabditis elegans . Mol Cells 26:344–349[PubMed]
     [Google Scholar]
  21. Kosovec J. E., Egorin M. J., Gjurich S., Beumer J. H. 2008; Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 22:224–230 [View Article][PubMed]
     [Google Scholar]
  22. Longley D. B., Harkin D. P., Johnston P. G. 2003; 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–338 [View Article][PubMed]
     [Google Scholar]
  23. Lucas V. S., Beighton D., Roberts G. J., Challacombe S. J. 1997; Changes in the oral streptococcal flora of children undergoing allogeneic bone marrow transplantation. J Infect 35:135–141 [View Article][PubMed]
     [Google Scholar]
  24. Marsh P., Martin M. V. 1999 Oral Microbiology London: Chapman & Hall;
     [Google Scholar]
  25. Mechergui A., Achour W., Baaboura R., Ouertani H., Lakhal A., Torjemane L., Othman T. B., Hassen A. B., Ben Othman T., Ben Hassen A. 2014; Case report of bacteremia due to Neisseria mucosa . APMIS 122:359–361 [View Article][PubMed]
     [Google Scholar]
  26. Napeñas J. J., Brennan M. T., Coleman S., Kent M. L., Noll J., Frenette G., Nussbaum M. L., Mougeot J. -L., Paster B. J. et al. 2010; Molecular methodology to assess the impact of cancer chemotherapy on the oral bacterial flora: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 109:554–560 [View Article]
     [Google Scholar]
  27. Omura K. 2003; Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol 8:132–138 [View Article][PubMed]
     [Google Scholar]
  28. Panghal M., Kaushal V., Kadayan S., Yadav J. P. 2012; Incidence and risk factors for infection in oral cancer patients undergoing different treatments protocols. BMC Oral Health 12:12 [View Article]
     [Google Scholar]
  29. Peterson D. E., Sonis S. T. 1982; Oral complications of cancer chemotherapy: present status and future studies. Cancer Treat Rep 66:1251–1256[PubMed]
     [Google Scholar]
  30. Saif M. W., Choma A., Salamone S. J., Chu E. 2009; Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst 101:1543–1552 [View Article][PubMed]
     [Google Scholar]
  31. Salonga D., Danenberg K. D., Johnson M., Metzger R., Groshen S., Tsao-Wei D. D., Lenz H. J., Leichman C. G., Leichman L. et al. 2000; Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322–1327[PubMed]
     [Google Scholar]
  32. Stringer A. M., Gibson R. J., Logan R. M., Bowen J. M., Yeoh A. S., Hamilton J., Keefe D. M. 2009; Gastrointestinal microflora and mucins may play a critical role in the development of 5-fluorouracil-induced gastrointestinal mucositis. Exp Biol Med 234:430–441 [View Article][PubMed]
     [Google Scholar]
  33. Stringer A. M., Logan R. M. 2015; The role of oral flora in the development of chemotherapy-induced oral mucositis. J Oral Pathol Med 44:81–87 [View Article][PubMed]
     [Google Scholar]
  34. Takahata M., Yamashiro Y., Yotsuji A., Fukuoka Y., Yasuda T., Saikawa I., Ueda Y. 1986; Enhancement of 5-fluorouracil uptake into the bacterial cell by piperacillin. J Antibiot 39:1167–1171 [View Article][PubMed]
     [Google Scholar]
  35. Takechi T., Uchida J., Fujioka A., Fukushima M. 1997; Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumor cells. Int J Oncol 11:1041–1044 [View Article][PubMed]
     [Google Scholar]
  36. Takimoto C. H., Lu Z. H., Zhang R., Liang M. D., Larson L. V., Cantilena L. R., Grem J. L., Allegra C. J., Diasio R. B., Chu E. 1996; Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 2:477–481[PubMed]
     [Google Scholar]
  37. Takimoto C. H., Yee L. K., Venzon D. J., Schuler B., Grollman F., Chabuk C., Hamilton J. M., Chen A. P., Allegra C. J., Grem J. L, Green J. L. 1999; High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion. Clin Cancer Res 5:1347–1352[PubMed]
     [Google Scholar]
  38. Ueda Y., Saito A., Fukuoka Y., Yamashiro Y., Ikeda Y., Taki H., Yasuda T., Saikawa I. 1983; Interactions of beta-lactam antibiotics and antineoplastic agents. Antimicrob Agents Chemother 23:374–378 [View Article][PubMed]
     [Google Scholar]
  39. Van Nevel S., Koetzsch S., Weilenmann H. U., Boon N., Hammes F. 2013; Routine bacterial analysis with automated flow cytometry. J Microbiol Methods 94:73–76 [View Article][PubMed]
     [Google Scholar]
  40. Vanhoecke B., De Ryck T., Stringer A., Van de Wiele T., Keefe D. 2015; Microbiota and their role in the pathogenesis of oral mucositis. Oral Dis 21:17–30 [View Article][PubMed]
     [Google Scholar]
  41. Villa A., Sonis S. T. 2015; Mucositis: pathobiology and management. Curr Opin Oncol 27:159–164 [View Article][PubMed]
     [Google Scholar]
  42. Von Bültzingslöwen I., Adlerberth I., Wold A. E., Dahlén G., Jontell M. 2003; Oral and intestinal microflora in 5-fluorouracil treated rats, translocation to cervical and mesenteric lymph nodes and effects of probiotic bacteria. Oral Microbiol Immunol 18:278–284 [View Article][PubMed]
     [Google Scholar]
  43. Wescombe P. A., Hale J. D., Heng N. C., Tagg J. R. 2012; Developing oral probiotics from Streptococcus salivarius . Future Microbiol 7:1355–1371 [View Article][PubMed]
     [Google Scholar]
  44. West T. P. 1998; Isolation and characterization of an Escherichia coli B mutant strain defective in uracil catabolism. Can J Microbiol 44:1106–1109 [View Article][PubMed]
     [Google Scholar]
  45. Wright D. N., Matsen J. M. 1980; Bioassay of antibiotics in body fluids from patients receiving cancer chemotherapeutic agents. Antimicrob Agents Chemother 17:417–422 [View Article][PubMed]
     [Google Scholar]
  46. Zijnge V., van Leeuwen M. B., Degener J. E., Abbas F., Thurnheer T., Gmür R., Harmsen H. J., M. Harmsen H. J. 2010; Oral biofilm architecture on natural teeth. PLoS One 5:e9321 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000292
Loading
5-Fluorouracil sensitivity varies among oral micro-organisms
J. Med. Microbiol. 65, 775 (2016); https://doi.org/10.1099/jmm.0.000292
/content/journal/jmm/10.1099/jmm.0.000292
/content/journal/jmm/10.1099/jmm.0.000292
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error